Abstract Details

Title Real-world Idiopathic Hypersomnia Total Health Model (RHYTHM): Clinical Burden of Patients Diagnosed with Idiopathic Hypersomnia

Topic Sleep

Presentation(s) S36 - Sleep Neurology Highlights (5:06 PM-5:18 PM)

Poster/Presentation
Number 009

Background IH is a rare neurologic disorder characterized by excessive daytime sleepiness; sleep inertia; prolonged nighttime sleep; long, unrefreshing naps; and cognitive dysfunction. Limited research investigates the clinical burden of IH.

Objective To compare comorbid conditions between patients with idiopathic hypersomnia (IH) and matched non-IH controls.

Design/Methods Merative MarketScan claims were analyzed (study period, 12/31/2013–2/29/2020; index period, 12/31/2014–3/1/2019). Eligible patients with IH were ≥18 years of age, continuously enrolled (gaps ≤30 days allowed), and without cataplexy. Patients entered the IH cohort upon receipt of their earliest medical claim with a diagnosis for IH in any position. Patients with IH were matched 1:5 with non-IH controls on age, sex, region, payer, and cohort entry date. Odds ratios (ORs) of comorbid conditions during the 2-year period (365 days before and after cohort entry) were compared using logistic regression; matching criteria were included as model covariates. ORs and 95% confidence intervals (CIs) were reported.

Results

Final cohorts included 11,412 patients with IH and 57,058 matched non-IH controls. Most patients were female (65.0%), and median age was 45 years. Patients with IH had higher odds of experiencing comorbid conditions across multiple clinical categories, from neoplasms (OR, 1.59 [1.52-1.66]) to nervous system diseases (OR, 4.36 [4.13-4.60]), than non-IH controls. Odds of comorbid sleep conditions in patients with IH, including sleep apnea (OR, 25.43 [24.11-26.82]), periodic limb movement (OR, 32.99 [28.02-38.85]), and rapid eye movement behavior disorder (OR, 46.43 [28.80-80.21]), were higher than in matched non-IH controls. Patients with IH had higher odds of comorbid cardiovascular conditions, including stroke (OR, 2.07 [1.87-2.29]), major adverse cardiovascular events (OR, 2.08 [1.89-2.30]), and history of cardiovascular disease (OR, 2.26 [2.14-2.38]).

Conclusions Patients with IH experience several comorbid conditions, including cardiovascular and sleep conditions, and nervous system diseases. Consideration of patients’ comorbidities may be relevant when evaluating treatment options for patients with IH.

Authors/Disclosures
Jed Black, MD (Jazz Pharmaceuticals) PRESENTER	Jed Black, MD has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Jed Black, MD has stock in Jazz Pharmaceuticals. Jed Black, MD has stock in .
Prasheel Lillaney	No disclosure on file
Ragy Saad (Jazz Pharmaceuticals)	No disclosure on file
Deb Profant (Jazz Pharmaceuticals)	No disclosure on file
Douglas S. Fuller (Jazz Pharmaceuticals)	Mr. Fuller has received personal compensation for serving as an employee of Jazz Pharmaceuticals. Mr. Fuller has stock in Jazz Pharmaceuticals.
Trevor Alvord	No disclosure on file
Patricia Prince (Aetion)	No disclosure on file
Marisa Whalen	Marisa Whalen has received personal compensation for serving as an employee of Jazz Pharmaceuticals.
Wayne Macfadden, MD, PT	Dr. Macfadden has received personal compensation for serving as an employee of Jazz pharma. Dr. Macfadden has stock in Jazz pharma.
Weiyi Ni	No disclosure on file